Dietary supplement interactions with medications used commonly in dentistry

Journal of the American Dental Association

Volumn 144, Issue 7, 2013, Pages 787-794

  Donaldson, Mark ^a,b,c   Touger Decker, Riva ^d,e  

^a KALISPELL REGIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Dentistry; Diet; Dietary supplements; Drugs; Interactions

Indexed keywords

BIOMEDICAL AND DENTAL MATERIALS; DRUG;

ARTICLE; DENTISTRY; DIET; DIET SUPPLEMENTATION; FOOD DRUG INTERACTION; HERB DRUG INTERACTION; HUMAN; INTERACTIONS; PHYTOTHERAPY; RISK ASSESSMENT;

DENTISTRY; DIET; DIETARY SUPPLEMENTS; DRUGS; INTERACTIONS;

DIETARY SUPPLEMENTS; FOOD-DRUG INTERACTIONS; HERB-DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS, DENTAL; PHYTOTHERAPY; RISK ASSESSMENT;

EID: 84881110051     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2013.0188     Document Type: Article

References (90)

1. National Institutes of Health State-of-the-Science Panel. National Institutes of Health State-of-the-Science Conference Statement: multivitamin/mineral supplements and chronic disease prevention. Am J Clin Nutr 2007;85(1):257S-264S.
2. Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003-2006 (published online ahead of print Dec. 22, 2010). J Nutr 2011;141(2):261-266. doi:10.3945/jn. 110.133025.
3. U. S. Department of Health and Human Services, U. S. Food and Drug Administration. Q & Aon dietary supplements, www.fda.gov/Food/ DietarySupplements/QADietaiySupplements/ucml91930.htm#. Accessed Aug. 26, 2012.
4. Trading down in multivitamins. Nutrition Business Journal. http://newhope360.com/8ite-files/newhope360.com/files/uploads/2011/08/ NBJSampleIssue2011.pdf. Accessed May 3, 2013.
5. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287(3):337-344.
6. Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 2006;166(18):1968-1974.
7. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365(21):2002-2012.
8. Patterns of Medication Use in the United States 2006: A Report From the Slone Survey. Boston: Slone Epidemiology Center at Boston University. www.bu.edu/slone/files/2012/11/SloneSurvey Report2006.pdf. Accessed Aug. 26, 2012.
9. El Desoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther 2007;14(5):488-498.
10. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56(2):163-184.
11. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296(15):1858-1866.
12. U. S. Department of Health and Human Services, National Institutes of Health, National Center for Complementary and Alternative Medicine (NCCAM). Complementary and alternative medicine: what people aged 50 and older discuss with their health care providers, http://nccam.nih.gov/new8/camstats/2010/ introduction. htm. Accessed April 24, 2013.
13. Bonakdar RA. The H. E. R. B. A. L. mnemonic: introduction and overview. In: Bonakdar RA, ed. The H. E. R. B. A. L. Guide: Dietary Supplement Resources for the Clinician. Philadelphia: Lippincott Williams & Wilkins; 2010:1-2.
14. Lexicomp. Lexicomp online for dentistry, http://webstore.lexi.com/ONLINE- Software-for-Dentists. Philadelphia: Wolters Kluwer Health; Accessed May 1, 2013.
15. Natural Medicines Comprehensive Database. About Natural Medicines Comprehensive Database, http://naturaldatabase.therapeuticresearch.com/Content. aspx?cs=&s=ND&page=aboutdbhtml&xsl=generic#ratings. Accessed May 2, 2013.
16. Donaldson M, Goodchild JH. Pregnancy, breast-feeding and drugs used in dentistry (published correction appears in JADA 2012;143[11]:1187). JADA 2012;143(8):858-871.
17. Rosenberg M. Preparing for medical emergencies: the essential drugs and equipment for the dental office. JADA 2010;141(suppl 1):14S-19S.
18. Blumenthal M, Lindstrom A, Lynch ME, Rea P. Herb sales continue growth: up 3.3% in 2010. HerbalGram 2011;90:64-67. http://cms.herbalgram.org/herbalgram/ issue90/MarketReport.html. Accessed April 23, 2013.
19. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altem Ther Health Med 2005;11(1):42-49.
20. Radler DR. Dietary supplements: clinical implications for dentistry. JADA 2008;139(4):451-455.
21. Singh SR, Levine MA. Potential interactions between pharmaceuticals and natural health products in Canada. J Clin Pharmacol 2007;47(2):249-258.
22. Ismail AI, Bader JD; ADA Council on Scientific Affairs and Division of Science. Evidence-based dentistry in clinical practice. JADA 2004;135(1):78-83.
23. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract (letter). N Engl J Med 1997;336(15):1108.
24. Bebbington A, Kulkarni R, Roberts P. Ginkgo biloba: persistent bleeding after total hip arthroplasty caused by herbal self-medication. J Arthroplasty 2005;20(1):125-126.
25. Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs R D 2006;7(3):163-172.
26. Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis 2007;18(8):787-793.
27. Beckert BW, Concannon MJ, Henry SL, Smith DS, Puckett CL. The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plast Reconstr Surg 2007;120(7):2044-2050.
28. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46(6):1775-1776.
29. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998;352(9121):36.
30. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage (letter). Neurology 1998;50(6):1933-1934.
31. Gilbert GJ. Ginkgo biloba (letter). Neurolop' 1997;48(4):1137.
32. Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001;67(1):33-35.
33. Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage: can Ginkgo biloba be implicated? Postgrad Med J 2001;77(904):112-113.
34. Jayasekera N, Moghal A, Kashif F, Karalliedde L. Herbal medicines and postoperative haemorrhage. Anaesthesia 2005;60(7):725-726.
35. Spolarich AE, Andrews L. An examination of the bleeding complications associated with herbal supplements, antiplatelet and anticoagulant medications. J Dent Hyg 2007;81(3):67.
36. Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008;9(10):1063-1120.
37. Markowitz JS, Donovan JL, De Vane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290(11):1500-1504.
38. Carrasco MC, Vallejo JR, Pardo-de-Santayana M, Peral D, Martín MA, Altimiras J. Interactions of Valeriana officinalis L. and Passiflora incamata L. in a patient treated with lorazepam (published online ahead of print May 13, 2009). Phytother Res 2009;23(12):1795-1796. doi:10.1002/ptr.2847.
39. Khom S, Baburin I, Timin E, et al. Valerenic acid potentiates and inhibits GABA (A) receptors: molecular mechanism and subunit specificity (published online ahead of print May 13, 2007). Neuropharmacology 2007;53(1):178-187. doi:10.1016/j.neuropharm. 2007.04.018.
40. Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G. Modulation of the Y-aminobutyric acid (GABA) system by Passiflora incarnata L. (published online ahead of print Nov. 19, 2010). Phytother Res 2011;25(6):838-843. doi:10.1002/ptr.3352.
41. Gutierrez S, Ang-Lee MK, Walker DJ, Zacny JP. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol Biochem Behav 2004;78(1):57-64.
42. Ugalde M, Reza V, González-Trujano ME, Avula B, Khan IA, Navarrete A. Isobolographic analysis of the sedative interaction between six central nervous system depressant drugs and Valeriana edulis hydroalcoholic extract in mice. J Pharm Pharmacol 2005;57(5):631-639.
43. Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine 2008;15(1-2):2-15.
44. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158(20):2200-2211.
45. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum)', drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54(4):349-356.
46. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72(3):276-287.
47. Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003;10(4):334-342.
48. Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004;32(5):512-518.
49. Upton R, ed. St. John's Wort: Hypericum perforatum. Quality Control, Analytical and Therapeutic Monograph. Santa Cruz, Calif.: American Herbal Pharmacopoeia; 1997:1-32.
50. Hussain MD, Teixeira MG. Saint John's wort and analgesia: effect of Saint John's wort on morphine induced analgesia (presentation 3453). Poster presented at: American Association of Pharmaceutical Scientists 2000 Annual Meeting and Exposition; Oct. 29-Nov. 2, 2000; Indianapolis.
51. Houghton PJ. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 1999;51(5):505-512.
52. Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 2004;98(2):353-358.
53. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70(4):317-326.
54. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001;8(2):152-160.
55. Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53(1):75-82.
56. Diirr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDRl and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68(6):598-604.
57. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34(1-2):47-54.
58. Matón PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;57(6):855-870.
59. Tetracycline hydrochloride capsules USP (package insert). Sellersville, Pa.: TEVA Pharmaceuticals USA; 2009.
60. Minocin (package insert). Cranford, N. J.: Triax Pharmaceuticals; 2010.
61. Vibramycin (package insert). New York City: Pfizer; 2007.
62. PhosLo (package insert). Waltham, Mass.: Fresenius Medical Care North America; 2011.
63. Jung H, Peregrina AA, Rodriguez JM, Moreno-Esparza R. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm Drug Dispos 1997;18(5):459-463.
64. Budzinski JW, Foster BC, Vandenhoek S, Aroason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7(4):273-282.
65. Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan SA. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 2004;7(2):265-273.
66. Donovan JL, De Vane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers (published online ahead of print Aug. 24, 2004). Drug Metab Dispos 2004;32(12):1333-1336. doi:10.1124/dmd.104. 001164.
67. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005;77(5):415-426.
68. Guivemau M, Meza N, Baija P, Roman O. Clinical and experimental study on the long-term effect of dietary gamma-linolenic acid on plasma lipids, platelet aggregation, thromboxane formation, and prostacyclin production. Prostaglandins Leukot Essent Fatty Acids 1994;51(5):311-316.
69. Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 2003;167(2):367.
70. Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 2011;31(5):490-502.
71. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altera Complement Med 2005;11(3):433-439.
72. Gaudineau C, Beckerman R, Welboum S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 2004;318(4):1072-1078.
73. Mohutsky MA, Anderson GD, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 2006;13(1):24-31.
74. Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. Thromb Res 2002;108(2-3):151-160.
75. Miller LG, Freeman B. Possible subdural hematoma associated with Ginkgo biloba. J Herb Pharmacother 2002;2(2):57-63.
76. Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. J Gen Intern Med 2005;20(7):657-661.
77. Bell EC, Ravis WR, Lloyd KB, Stokes TJ. Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. Ann Pharmacother 2007;41(2):229-234.
78. Nieminen TH, Hagelberg NM, Saari TI, et al. St John's wort greatly reduces the concentrations of oral oxycodone (published online ahead of print Jan. 27, 2010). Eur J Pain 2010;14(8):854-859. doi: 10.1016/j.ejpain. 2009.12.007.
79. Yue QY, Bergquist C, Gerdin B. Safety of St John's wort CHypericum perforatum) (letter). Lancet 2000;355(9203):576-577.
80. Jaffe JM, Poust RI, Feld SL, Colaizzi JL. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci 1974;63(8):1256-1260.
81. Rosenblatt JE, Barrett JE, Brodie JL, Kirby WM. Comparison of in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother (Bethesda) 1966;6:134-141.
82. Albert KS, Welch RD, De Sante KA, Di Santo AR. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrhea] mixture. J Pharm Sci 1979;68(5):586-588.
83. Barr WH, Adir J, Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. Clin Pharmacol Ther 1971;12(5):779-784.
84. Albert A, Rees CW. Avidity of the tetracyclines for the cations of metals. Nature 1956;177(4505):433-434.
85. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67(5):451-457.
86. Winter ME. Elimination rate constant (K) and half-life (tV4). In: Winter ME. Basic Clinical Pharmacokinetics. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2010:39-53.
87. Kleinen J, Knipschild P. Ginkgo biloba (letter). Lancet 1992;340(8828):1136-1139.
88. Barnes J, Anderson LA, Phillipson JD. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001;53(5):583-600.
89. Martens-Lobenhoffer J, Meyer FP. Pharmacokinetic data of gamma-linolenic acid in healthy volunteers after the administration of evening primrose oil (Epogam). Int J Clin Pharmacol Ther 1998;36(7):363-366.
90. Anderson GD, Elmer GW, Taibi DM, et al. Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women (published online ahead of print April 13, 2010). Phytother Res 2010;24(10):1442-1446. doi:10.1002/ptr.3151.